Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer

Primary Sponsor

ANZUP

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre

Accrual Target

800

Final Accrual

802

Closing Date of Accrual

30 June 2018

Trial Contact

enzarad.study@sydney.edu.au

Related Post

21 October, 2025

Grandad’s mission to walk 10,000 steps a day to support cancer research

LATEST NEWS: 21 October 2025 Walking at least 10,000

Prof Wee Loon Ong
24 September, 2025

Prostate Cancer Month: Focus on the TROG Genitourinary Working Party

To mark Prostate Cancer Month in September, we asked